AKR7A3 inhibits the tumorigenicity and chemoresistance of hepatic carcinoma by attenuating ERK, c-Jun, and NF-κB signaling pathways (Chow et al., 2017). Here, NFKB1 is linked to hepatocellular carcinoma.